text_1: The treatment of cancer patients with co-IR blockade does not cause any adverse autoimmune events.
text_2: However, as the use of immunotherapy becomes more common, especially as first- and second-line treatments, immunotoxicity and autoimmunity are emerging as the Achilles' heel of immunotherapy.